secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aurinia Pharmaceuticals Inc. (AUPH)
CIK:        0001600620
Form:       8-K
Filed at:   2026-03-23T23:59:59+00:00
Accession:  0001600620-26-000026
Event type: leadership
Sentiment:  neutral
Materiality: 0.85
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aurinia appoints Chair Kevin Tang as CEO; entire C-suite replaced effective March 23, 2026
--------------------------------------------------------------------------------

- Kevin Tang (Chair) appointed CEO, succeeding Peter Greenleaf; Greenleaf to consult for 3 months at $600/hr.
- Ryan Cole appointed COO ($300k salary, 50% bonus, 150k options); Michael Hearne appointed CFO (same terms).
- Departures: Peter Greenleaf, Matthew Donley (COO), Gregory Keenan (CMO), Joseph Miller (CFO) effective March 20-21.
- Thomas Wei appointed Chief Scientific Officer; Craig Johnson elected Lead Independent Director.
- Kevin Tang will receive no salary, bonuses, or equity for his CEO role.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1600620/000160062026000026/0001600620-26-000026-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1600620/000160062026000026/auph-20260320.htm
  HTML page:      https://secwatch.observer/filing/0001600620-26-000026

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer